Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.67 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.66 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.66 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.64 |
| ▸ | PPARG | P37231 | 7/20 | 0.64 |
| ▸ | PPARD | Q03181 | 7/20 | 0.64 |
| ▸ | PPARA | Q07869 | 7/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.64 |
| ▸ | TSHR | P16473 | 4/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | TLR2 | O60603 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | FABP4 | P15090 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.64 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | ESR1 | P03372 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7549169 | 0.98 | FFAR4 (0.69) | AKR1B1FFAR4FFAR1GPR84PPARG | |
| SCHEMBL6858975 | 0.98 | FFAR4 (0.69) | AKR1B1FFAR4FFAR1GPR84PPARG | |
| SCHEMBL6859751 | 0.98 | FFAR4 (0.69) | AKR1B1FFAR4FFAR1GPR84PPARG | |
| SCHEMBL5878967 | 0.98 | FFAR4 (0.69) | AKR1B1FFAR4FFAR1GPR84PPARG | |
| SCHEMBL5878858 | 0.98 | FFAR4 (0.69) | AKR1B1FFAR4FFAR1GPR84PPARG | |
| SCHEMBL25188025 | 0.98 | FFAR4 (0.69) | AKR1B1FFAR4FFAR1GPR84PPARG | |
| SCHEMBL16213066 | 0.98 | FFAR4 (0.69) | AKR1B1FFAR4FFAR1GPR84PPARG | |
| SCHEMBL5878779 | 0.98 | FFAR4 (0.69) | AKR1B1FFAR4FFAR1GPR84PPARG | |
| SCHEMBL6859924 | 0.98 | FFAR4 (0.69) | AKR1B1FFAR4FFAR1GPR84PPARG | |
| SCHEMBL5878821 | 0.98 | FFAR4 (0.69) | AKR1B1FFAR4FFAR1GPR84PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| EP-2992031-B1 | ALIPHATIC POLYCARBONATE COMPOSITIONS AND METHODS | NOVOMER INC (US) | 2022-10-05 | — | — | EP | disclosed |
| US-9738760-B2 | Aliphatic polycarbonate compositions and methods | NOVOMER, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| CN-105518053-B | aliphatic polycarbonate compositions and methods | 诺沃梅尔公司 | 2017-07-21 | — | — | CN | disclosed |
| CN-105518053-A | Aliphatic polycarbonate compositions and methods | NOVOMER INC | 2016-04-20 | — | — | CN | disclosed |
| US-20160068638-A1 | ALIPHATIC POLYCARBONATE COMPOSITIONS AND METHODS | NOVOMER, INC. | 2016-03-10 | — | — | US | disclosed |
| EP-2992031-A2 | ALIPHATIC POLYCARBONATE COMPOSITIONS AND METHODS | Novomer, Inc. (US) | 2016-03-09 | — | — | EP | disclosed |
| WO-2014178972-A2 | ALIPHATIC POLYCARBONATE COMPOSITIONS AND METHODS | NOVOMER, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | AKR1B1 3777/4885FFAR4 1899/4885FFAR1 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.